Home › NCT07673120

A Study to Assess Safety, Tolerability, and How Single and Multiple Injections or Infusions of ABBV-313 Affects the Body of Adult Participants

A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single Ascending Doses and Multiple Doses of ABBV-313

Who can join

Ages 18 to 55 · All sexes · Healthy volunteers welcome

Inclusion Criteria:

* BMI is \>= 18.0 to \<= 29.9 kg/m2 after rounding to the tenths decimal at Screening. BMI is calculated as weight in kg divided by the square of height measured in meters.
* A condition of general good health, based upon the results of a medical history, physical examination, vital signs, laboratory profile and a 12-lead ECG.

Exclusion Criteria:

* History of any clinically significant sensitivity or allergy to any medication or food.
* History of any clinically significant illness/infection/major febrile illness, hospitalization, or any surgical procedure within 30 days prior to the first dose of study treatment.
* Participant has prior exposure to ABBV-313 within the past 300 days.

About the study

The objective of this study is to assess the safety, tolerability, pharmacokinetics, and immunogenicity of single and multiple doses of ABBV-313 in healthy adult participants.

What is being tested

• ABBV-313 (drug)
• Placebo (drug)
• ABBV-313 (drug)
• Placebo (drug)

Sponsor: AbbVie · Participants: 64 · Started: Jun 24, 2026

Contact the study team

• ABBVIE CALL CENTER · Phone: 844-663-3742

Official record on ClinicalTrials.gov — NCT07673120

Locations in the U.S.

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.